Evaluation of a Mushroom-Derived Nutraceutical for Canine Cognitive Decline (CCD): A Nutraceutical for Canine Cognitive Decline (CCD)

Abstract

A persistent challenge in veterinary medicine is the limited availability of objective data supporting functional supplements such as nutraceuticals, mushrooms and herbal remedies. While many nature-derived interventions have long histories of anecdotal success and are gaining support from scientific research, veterinarians and pet owners seek stronger, current evidence to guide their use alongside-or in place of-conventional medications. Objective: To evaluate the efficacy of a proprietary mushroom extract formulated to support cognitive health in aging dogs. Methods: Client-owned dogs showing signs of cognitive decline were enrolled in a virtual, single-arm, open-label, prospective observational trial. Owner-reported cognitive assessments were combined with objective wearable activity monitoring. Novel biomarkers (CRP, BDNF) were included in several cases. Data were analyzed to assess changes in age-related behaviors, activities and biomarker values over the study period. Results: The integration of subjective, objective and biomarker data provided clinically meaningful insights into the cognitive, behavioral and emotional benefits of the mushroom extract. While biomarker evidence was limited and has yet to be fully validated, the positive subjective and objective results support further investigation with larger cohorts and more rigorous biomarker evaluation. Conclusion: This study adds real-world evidence for the use of an all-natural mushroom extract to support cognitive health in aging dogs. The findings may help veterinarians and pet owners feel more confident incorporating natural products into care decisions for aging companion animals.